Genetic variation may increase risk of liver damage in patients with chronic hepatitis B

July 27, 2018, Westmead Institute for Medical Research
First author Dr. Rasha El Sharkawy. Credit: The Westmead Institute for Medical Research

A new study has shown that genetic variation may increase the risk of severe liver damage in Caucasians with chronic hepatitis B infection.

Researchers from the Westmead Institute for Medical Research found that Caucasian patients with a variation in their STAT4 gene were more likely to experience inflammation and severe liver fibrosis.

Dr. Rasha El Sharkawy, the first author of the study, said the findings add to the growing body of evidence that demonstrates a link between genes and the progression of hepatitis B.

"The progression of liver injury in hepatitis B can vary significantly among patients, which indicates that genetic factors may play a role," Dr. El Sharkawy said.

The STAT4 gene is part of the body's immune response against viruses and regulates tissue inflammation, fibrosis and anti-viral activity.

"We found that patients with the risk had lower expression of STAT4 in their liver and immune cells, reducing their immune response against hepatitis B and their production of interferon gamma, a protein responsible for moderating fibrosis.

"This may, at least partially explain why patients with the variation experience poorer liver health," Dr. El Sharkawy explained.

Approximately one third of the world's population have come into contact with hepatitis B, with 350-400 million people developing a chronic infection. If left untreated, can lead to liver injury, liver cancer, and liver failure, with more than one million deaths attributed to cirrhosis and cancer each year.

"Not everyone who comes into contact with the virus will develop a chronic infection, but those that do, require treatment to prevent severe complications, including and damage," Dr. El Sharkawy said.

Professor Jacob George and Associate Professor Mohammed Eslam, leaders of the research study, said that with further study, researchers could better understand how the STAT4 gene affects the progression of B, so that they can prevent and failure in at-risk groups.

Explore further: Can aspirin stop liver cancer in hepatitis B patients?

More information: R. El Sharkawy et al, A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B, Alimentary Pharmacology & Therapeutics (2018). DOI: 10.1111/apt.14866

Related Stories

Can aspirin stop liver cancer in hepatitis B patients?

October 20, 2017
(HealthDay)—Daily aspirin may reduce the risk of liver cancer for people with hepatitis B infection, a new study suggests.

Risk of liver cancer from hepatitis B persists even after clearing the virus

April 22, 2016
Long-term infection with hepatitis B virus (HBV) can cause liver inflammation and increase the risk of liver cancer. Researchers from the US Centers for Disease Control and Prevention, however, found that resolving HBV infection ...

World-first discovery of protein that causes liver disease brings hope for new treatments

May 24, 2017
In a world-first discovery, scientists at Sydney's Westmead Institute for Medical Research have identified a protein that causes liver fibrosis (scarring), paving the way for new treatments for liver disease to be developed.

Hepatitis C remains major problem for HIV patients despite antiretroviral therapy

March 17, 2014
A new study led by researchers at the Perelman School of Medicine at the University of Pennsylvania has found that the risk of hepatitis C-associated serious liver disease persists in HIV patients otherwise benefitting from ...

Zinc may hold key to fighting liver disease

June 1, 2017
New research from the Westmead Institute's Storr Liver Centre in collaboration with the Centre for Virus Research and Kirby Institute has shown that serum zinc may benefit liver disease in a way we never expected.

Study finds molecules present possible biomarkers of HCV-related liver damage progression

October 25, 2017
Hepatitis C virus infection leads to a wide spectrum of liver diseases ranging from mild chronic hepatitis to end-stage cirrhosis and hepatocellular carcinoma. An intriguing aspect of the HCV infection is its close connection ...

Recommended for you

Tibetan sheep highly susceptible to human plague, originates from marmots

August 16, 2018
In the Qinghai-Tibet plateau, one of the region's highest risk areas for human plague, Himalayan marmots are the primary carriers of the infectious bacterium Y. pestis. Y. pestis infection can be transmitted to humans and ...

Autoimmunity plays role in development of COPD, study finds

August 16, 2018
Autoimmunity plays a role in the development of chronic obstructive pulmonary disease (COPD), according to a study led by Georgia State University and Vanderbilt University Medical Center that analyzed human genome information ...

Scientists identify nearly 200 potential tuberculosis drug targets

August 16, 2018
Tuberculosis is one of the top 10 causes of death worldwide. Nearly 2 million people die every year from this infectious disease, and an estimated 2 billion people are chronically infected. The only vaccine, developed almost ...

Reliable point-of-care blood test can help prevent toxoplasmosis

August 16, 2018
A recent study, performed in Chicago and Rabat, Morocco, found that a novel finger-prick test for infection with the parasite Toxoplasma gondii during pregnancy—and many other potential applications—is 100 percent sensitive ...

First mouse model to mimic lung disease could speed discovery of more effective treatments

August 16, 2018
The biggest hurdle to finding effective therapies for idiopathic pulmonary fibrosis (IPF) – a life-threatening condition in which the lungs become scarred and breathing is increasingly difficult – has been the inability ...

Anticancer drug offers potential alternative to transplant for patients with liver failure

August 15, 2018
Patients suffering sudden liver failure could in the future benefit from a new treatment that could reduce the need for transplants, research published today shows.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.